Has Fernand Bteich, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,817 in general payments to Fernand Bteich, MD across 41 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Fernand Bteich, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Fernand Bteich, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Fernand Bteich, MD

Hematology & Oncology · Bronx, NYNPI 1770004269

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.1% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,656 and has fallen 78.6% since, to $354 in 2025.

$3,817in general payments, 2019–2025

Across 41 payments — averaging $93.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$891
AbbVie$581
Gilead$350
Regeneron Healthcare Solutions, Inc.$259
Daiichi Sankyo Inc.$249
E.r. Squibb & Sons, L.L.C.$247
plus $1K from 11 others

$289,636in research payments, 2019–2025

Across 45 payments — averaging $6436.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$184K
Genentech, Inc.$73K
Boehringer Ingelheim International GmbH$33K

What the payments were for

Food & beverage$3,43890%
Education$37910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	8	$891
AbbVie	7	$581
Gilead	3	$350
Regeneron Healthcare Solutions, Inc.	2	$259
Daiichi Sankyo Inc.	2	$249
E.r. Squibb & Sons, L.L.C.	2	$247
Seagen Inc.	2	$238
Takeda Pharmaceuticals U.S.A., Inc.	2	$202
Exelixis Inc.	1	$174
Novartis	5	$147
Genentech USA, Inc.	1	$116
Adaptive Biotechnologies Corporation	1	$104
AstraZeneca	1	$99
Genentech, Inc.	1	$79
Medtronic	1	$42
Deciphera Pharmaceuticals Inc.	1	$22
Merck	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,817 in reported general payments places this provider in the 60th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024

$33,510

Medicare patients

120

Services billed

305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XtandiEnzalutamide	11	$155,795
LoperamideLoperamide Hcl	29	$570
Ondansetron Hcl	33	$289
Oxycodone Hcl	19	$105
Prednisone	21	$46

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Bronx

Tauseef AhmedBronx$171K
Michael SchusterNew York$1.6M
Charles SawyersNew York$1.6M
Manuel Hidalgo-MedinaNew York$1.4M
Francis ArenaLake Success$1M
Sanjeev JainEast Patchogue$971K
Ross LevineNew York$968K
Perry CookBrooklyn$803K
Mihir RavalAlbany$767K
Joshua SabariNew York$761K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →